Pazopanib: a new drug for pancreatic neuroendocrine tumours
Mené sur 32 patients atteints d'une tumeur neuroendocrine du pancréas et 20 patients atteints d'une tumeur carcinoïde de stade avancé, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité de l'ajout du pazopanib à l'octréotide
Gastroenteropancreatic neuroendocrine tumours (NETs) are often stated to be rare. However, although their incidence is low, their prevalence is quite high because of their often indolent course. New treatment options for the large group of patients who have such tumours are therefore of great interest.
The Lancet Oncology , commentaire, 2014